Literature DB >> 8383542

p53 gene rearrangements in chronic myelocytic leukemia.

A Hernández1, P Hernández, L Corral, A Muñiz, C Alaez, E Espinosa, O Fernández, G Martinez.   

Abstract

We performed Southern-blot analysis of the p53 gene in 41 consecutive patients with typical chronic myelocytic leukemia (CML). In two of them, we were able to study cells during both the chronic and the accelerated phases. Only one of the 29 chronic-phase samples had rearrangement of the p53 gene, whereas three of the nine accelerated-phase samples and one of the five patients in blast crisis exhibited rearrangements. Gene deletion was observed in two patients, one in accelerated phase and the other in blast crisis. One patient with a nonrearranged p53 gene in chronic phase showed rearrangement after progression to the accelerated phase. On the other hand, one patient in accelerated phase exhibited rearrangements which disappeared after reversion to chronic phase with successful treatment. Our findings support the opinion that alterations of the p53 gene may play an important role in CML evolution.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383542     DOI: 10.1007/bf01695889

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  17 in total

1.  Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis.

Authors:  A Foti; H G Ahuja; S L Allen; P Koduru; M W Schuster; P Schulman; M Bar-Eli; M J Cline
Journal:  Blood       Date:  1991-06-01       Impact factor: 22.113

Review 2.  Clinical characteristics of the blast phase of chronic granulocytic leukemia.

Authors:  G P Canellos
Journal:  Hematol Oncol Clin North Am       Date:  1990-04       Impact factor: 3.722

3.  Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

Authors:  H Ahuja; M Bar-Eli; S H Advani; S Benchimol; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

4.  Primary structure polymorphism at amino acid residue 72 of human p53.

Authors:  G J Matlashewski; S Tuck; D Pim; P Lamb; J Schneider; L V Crawford
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

5.  Mutations of the P53 gene in acute myeloid leukaemia.

Authors:  P Fenaux; C Preudhomme; I Quiquandon; P Jonveaux; J L Laï; M Vanrumbeke; M H Loucheux-Lefebvre; F Bauters; R Berger; J P Kerckaert
Journal:  Br J Haematol       Date:  1992-02       Impact factor: 6.998

6.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

Review 7.  The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia.

Authors:  R Delage; J Ritz; K C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  1990-04       Impact factor: 3.722

8.  Alterations of the P53 gene are associated with the progression of a human prostate carcinoma.

Authors:  P J Effert; A Neubauer; P J Walther; E T Liu
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

9.  Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells.

Authors:  D Wolf; V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

10.  Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein.

Authors:  L V Crawford; D C Pim; E G Gurney; P Goodfellow; J Taylor-Papadimitriou
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

View more
  2 in total

1.  P53 tumor suppressor gene in chronic myelogenous leukemia: a sequential study.

Authors:  A Rovira; A Urbano-Ispizua; F Cervantes; M Rozman; J L Vives-Corrons; E Montserrat; C Rozman
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

2.  Genetic analysis of p53 and RB1 tumor-suppressor genes in blast crisis of chronic myeloid leukemia.

Authors:  G Gaidano; A Serra; A Guerrasio; G Rege-Cambrin; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-01       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.